After the FDA approved Gilead’s (GILD) Yeztugo for HIV prevention, Morgan Stanley analyst Terence Flynn said the label and pricing were in line with the firm’s expectations, calling the news “an expected positive.” The firm, which continues to see upside to the launch, reiterates an Overweight rating and $135 price target on Gilead shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Mizuho says Gilead Yeztugo label looks clean
- Gilead Sciences’ Yeztugo Approval and Market Expansion Drive Buy Rating
- Gilead announces FDA approves Yeztugo as twice-a-year HIV prevention option
- FDA approves Gilead’s Yeztugo for pre-exposure HIV prophylaxis
- Gilead receives FDA approval for HIV prevention injection